Assessment of Carbon Emission Impact of Semaglutide in Patients With Type 2 Diabetes in the United Kingdom Using an Innovative Modeling Approach
Value in Health · 2026
DOI: 10.1016/j.jval.2026.03.2249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2026. Verfasst von Niels Lund und 7 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk, Bagsvaerd, Denmark. Electronic address: nlnd@novonordisk.com. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Carbon Footprint. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Novo Nordisk.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVES: To evaluate the carbon footprint and clinical outcomes of once-weekly subcutaneous semaglutide in patients with type 2 diabetes mellitus (T2DM) in the United Kingdom. METHODS: Using the IQVIA Core Diabetes Model, environmental and clinical impacts were projected over a lifetime horizon from the National Health Services perspective. Data from the SUSTAIN-2 (patients with T2DM) and SUSTAIN-6 (patients with T2DM and established cardiovascular [CV] risk) trials were used to compare semaglutide with sitagliptin and placebo, respectively. Outcomes included life expectancy measured in life-years (LYs) and quality-adjusted life expectancy measured in quality-adjusted life-years (QALYs) gained, incidence of diabetes-related complications and adverse events, carbon emissions, and incremental carbon footprint effectiveness ratios. RESULTS: In patients with T2DM, semaglutide dominates sitagliptin, with higher discounted LYs (0.096) and QALYs (0.095) gains, a 6.9% reduction in diabetes-related complications and adverse events, and reduced lifetime carbon emissions by 9.3% (13,899 kg carbon dioxide equivalent emissions [CO2e] versus 15,319 kg CO2e). Similarly, in patients with T2DM and established CV risk, semaglutide showed higher discounted LYs (0.206) and QALYs (0.164), with reductions in all complications except heart failure-related hospitalizations versus placebo. Lifetime carbon emissions were 5.2% lower with semaglutide (14,546 kg CO2e versus 15,341 kg CO2e), again with a dominant carbon footprint effectiveness ratio. The reduction in CO2 was mainly driven by reduced complications and treatment needs. Sensitivity analyses supported the robustness of the results. CONCLUSION: Semaglutide offers environmental advantages over sitagliptin for patients with T2DM overall and over standard of care for those with established CV risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novo Nordisk, Bagsvaerd, Denmark. Electronic address: nlnd@novonordisk.com.
- Copenhagen Business School, Frederiksberg, Denmark.
- York Health Economics Consortium, University of York, York, England, UK.
- Novo Nordisk Ltd, Gatwick, England, UK.
- IQVIA, Amsterdam, Netherlands.
- IQVIA, Gurugram, Haryana, India.
Förderung
- Novo Nordisk
Zitieren
APA
Lund, N., Rasche, A., Taylor, M., Chubb, B., Xu, W., Taneja, L., Olivieri, A. V., & Sharma, Y. (2026). Assessment of Carbon Emission Impact of Semaglutide in Patients With Type 2 Diabetes in the United Kingdom Using an Innovative Modeling Approach. Value in Health. https://doi.org/10.1016/j.jval.2026.03.2249
Vancouver
Lund N, Rasche A, Taylor M, Chubb B, Xu W, Taneja L, et al. Assessment of Carbon Emission Impact of Semaglutide in Patients With Type 2 Diabetes in the United Kingdom Using an Innovative Modeling Approach. Value in Health. 2026. doi:10.1016/j.jval.2026.03.2249
BibTeX
@article{Lund2026,
author = {Lund, Niels and Rasche, Andreas and Taylor, Matthew and Chubb, Barrie and Xu, Weiwei and Taneja, Loveleen and Olivieri, Anamaria-Vera and Sharma, Yuvraj},
title = {Assessment of Carbon Emission Impact of Semaglutide in Patients With Type 2 Diabetes in the United Kingdom Using an Innovative Modeling Approach},
journal = {Value in Health},
year = {2026},
doi = {10.1016/j.jval.2026.03.2249}
}
EUVIMED